NEW YORK – Scandinavian private equity firm Summa Equity said Wednesday that it has acquired functional proteomics firm Sengenics.
Founded in 2008, Sengenics produces full-length folded protein arrays using its KREX protein folding technology. Currently, the company is focused on using the technology to discover autoantibody signatures that could be useful for detecting and managing autoimmune and infectious diseases and cancer.